XML 36 R26.htm IDEA: XBRL DOCUMENT v3.22.1
Revenue Recognition (Tables)
 3 Months Ended
Mar. 31, 2022
Revenue from Contract with Customer [Abstract]  
Summary of Contract Assets and Liabilities The following table summarizes the values of contract assets, capitalized commissions and contract liabilities (in thousands):
March 31, 2022December 31, 2021
Current pharma contract assets (1)
$1,643 $1,738 
Long-term pharma contract assets (2)
261 236 
Total pharma contract assets$1,904 $1,974 
Current pharma capitalized commissions (1)
$168 $109 
Long-term pharma capitalized commissions (2)
972 882 
Total pharma capitalized commissions$1,140 $991 
Current pharma contract liabilities$6,119 $5,192 
Long-term pharma contract liabilities (3)
1,081 917 
Total pharma contract liabilities$7,200 $6,109 
(1) Current pharma contract assets and Current pharma capitalized commissions are classified as other current assets on the Consolidated Balance Sheets.
(2) Long-term pharma contract assets and Long-term pharma capitalized commissions are classified as other assets on the Consolidated Balance Sheets.
(3) Long-term pharma contract liabilities are classified as other long-term liabilities on the Consolidated Balance Sheets.
Summary of Disaggregation of Revenue
The following table details the disaggregation of revenue for both the Clinical and Pharma Services Segments (in thousands):
Three Months Ended March 31,
20222021
Clinical Services:
    Client direct billing$65,014 $60,709 
    Commercial Insurance18,288 18,574 
    Medicare and Medicaid15,465 17,150 
    Self-Pay24 54 
Total Clinical Services $98,791 $96,487 
Pharma Services:18,378 19,046 
Total Revenue$117,169 $115,533